Valeant Pharmaceuticals International (VRX) 98.62

New Post Public Reply Private Reply Replies (0) Message Board

Oct 22, 2015 at 1:46 PM

Valeant Pharmaceuticals International (VRX) 98.62 $VRX

What Do Valeant, Amazon, Netflix and Yahoo! Have in Common?
at The Street - 1 hr 26 mins ago
Valeant faces accounting queries and Yahoo! took a writedown. Which companies will be next? Doug Kass thinks Amazon and Netflix look most at risk.
NFLX: 97.95 (-0.01), AMZN: 565.45 (+9.68), YHOO: 31.72 (+0.60), VRX: 98.62 (-19.99)

How Short Sellers Run this Market: Part 1
at The Street - 2 hrs 3 mins ago
First, the sectors where shorts are making big money.
KMI: 29.88 (-1.54), AGN: 252.45 (-6.55), HCA: 64.80 (-6.40), VRX: 98.62 (-19.99), SWKS: 81.03 (+3.36), CYH: 26.49 (-14.06), NXPI: 96.57 (+5.25), AVGO: 125.20 (+4.70), HRZN: 9.94 (+0.20)

No Easy Cure for What Ails Biotech Stocks
at The Street - 2 hrs 16 mins ago
Meanwhile, make incremental moves until the onslaught in the space is over.
BIIB: 279.54 (+3.20), VRX: 98.62 (-19.99), GILD: 102.63 (+0.90), MYL: 38.83 (-2.06), AMGN: 151.45 (+1.36)

INVESTIGATION REMINDER: Goldberg Law PC Announces an Investigation of Claims Against Valeant Pharmaceuticals International, Inc. and Encourages Investors to Contact the Firm
Business Wire - 2 hrs 41 mins ago
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company"

(NYSE: VRX). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
VRX: 98.62 (-19.99), VRX.TO: 129.04 (-25.17)

RBC Capital Markets Says Buy These 5 Pharmaceutical Stocks, Despite 'Irrational' Sell Off
at The Street - Thu Oct 22, 9:46AM CDT
The selloff in specialty pharmaceutical stocks has found a new "irrational low," following Wednesday's attack on Valeant Pharmaceuticals, according to RBC Capital Markets.
AGN: 252.45 (-6.55), ENDP: 49.48 (-4.98), INSY: 21.60 (-2.06), VRX: 98.62 (-19.99), SGNT: 15.23 (-0.83), IBB: 303.90 (-0.56), TEVA: 55.93 (-1.99)

Valeant Pharmaceuticals (VRX) Stock Collapses Further on Allegations Despite Ackman Stake
at The Street - Thu Oct 22, 9:45AM CDT
Valeant Pharmaceuticals (VRX) stock continues its crash on Thursday, after Citron Research alleged yesterday that the company has created a "phantom" pharmacies network to falsify sales and avoid auditor scrutiny.
VRX: 98.62 (-19.99)

Stock Market News for October 22, 2015
Zacks Equity Research - Zacks Investment Research - Thu Oct 22, 9:10AM CDT
Benchmarks ended Wednesday’s volatile trading session in the red following declines in healthcare and energy shares
KO: 43.57 (+1.38), KMI: 29.88 (-1.54), VRX: 98.62 (-19.99), MDT: 73.27 (-0.15), PFE: 33.16 (-0.30), UNH: 111.54 (-6.57), AMGN: 151.45 (+1.36), XOM: 82.34 (+2.13), COP: 54.55 (+1.58), BMY: 63.13 (+0.62), BA: 146.98 (+5.79), YHOO: 31.72 (+0.60), GM: 35.45 (+0.03), CVX: 91.59 (+2.26), OXY: 74.22 (+2.21)

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Valeant Pharmaceuticals International, Inc.
ACCESSWIRE - Thu Oct 22, 9:00AM CDT
NEW YORK, NY / ACCESSWIRE / October 22, 2015 / Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Valeant Pharmaceuticals International, Inc.("Valeant" or the "Company"

(NYSE: VRX). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
VRX: 98.62 (-19.99), VRX.TO: 129.04 (-25.17)

Downgrade Alert for Valeant Pharmaceuticals International (VRX)
Comtex SmarTrend(R) - Thu Oct 22, 8:06AM CDT
Valeant Pharmaceuticals International (NYSE:VRX) was downgraded from Outperform to Market Perform at BMO Capital today. The stock closed yesterday at $118.61 on volume of 88.3 million shares, above average daily volume of 6.1 million. Valeant Pharmaceuticals International is a research-based, specialty pharmaceutical company that markets its products worldwide. The Company discovers, develops, manufactures, and markets a range of pharmaceutical products, focusing on products in the areas of infectious disease, neurology, and dermatology.
VRX: 98.62 (-19.99)

Oct. 22 Premarket Briefing: 10 Things You Should Know
at The Street - Thu Oct 22, 5:46AM CDT
U.S. stock futures are rising and European shares trade mixed ahead of a European Central Bank policy meeting.
AMZN: 565.45 (+9.68), VRX: 98.62 (-19.99), AXP: 72.11 (-4.40), KORS: 39.60 (unch), INTC: 34.40 (+1.03), T: 34.00 (+0.40), EBAY: 27.55 (+3.34), JOE: 21.34 (+0.44), RHI: 50.08 (-2.31), LRCX: 72.50 (+1.71), MCD: 110.62 (+8.08), CFG: 23.43 (+0.26), GOOGL: 681.49 (+9.69), CAT: 71.64 (+1.97), MSFT: 48.68 (+1.48), RACE: 55.91 (+0.91), X: 11.24 (+0.39), UIL: 51.00 (+0.43)

For Valeant, the Selling Is Not Done
at The Street - Thu Oct 22, 4:28AM CDT
And it's weighing heavily on the whole of health care.
HLF: 55.03 (+0.22), VRX: 98.62 (-19.99)

'Fast Money' Recap: Don't Follow Bill Ackman Into Valeant
at The Street - Thu Oct 22, 4:00AM CDT
The trading panel discussed gambling on Valeant, oil stocks and Twitter.
VRX: 98.62 (-19.99), EBAY: 27.55 (+3.34), EOG: 85.86 (+2.08), APA: 45.69 (+0.61), XOM: 82.33 (+2.12), CVX: 91.59 (+2.26), TWTR: 29.30 (unch)

Valeant shares tumble as report questions company finances
By TOM MURPHY - AP - Wed Oct 21, 4:03PM CDT
Valeant Pharmaceuticals stock plunged Wednesday after Citron Research compared the Canadian pharmaceutical company to the collapsed energy giant Enron and accused it of creating a network of phantom pharmacies to fool auditors.
VRX: 98.62 (-19.99), VRX.TO: 129.04 (-25.17)

Valeant Dives As Short Seller Alleges Pharmacy Fraud
at Investor's Business Daily - Wed Oct 21, 4:02PM CDT
Embattled drugmaker Valeant Pharmaceuticals (VRX) tumbled nearly 40% Wednesday to a two-year low and closed down 19.2%, as short-selling outfit Citron Research charged it with a complex fraud involving multiple specialty pharmacies. Valeant responded...
AGN: 252.45 (-6.55), ENDP: 49.47 (-4.99), VRX: 98.62 (-19.99)

Work Ahead for Valeant to Get Back to 40-Week Average
at The Street - Wed Oct 21, 4:00PM CDT
Prices are trying hold around the $120 level, an older support area.
VRX: 98.62 (-19.99)

Biogen and SanDisk are big market movers
AP - Wed Oct 21, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
KO: 43.57 (+1.38), VRX: 98.62 (-19.99), LRCX: 72.50 (+1.71), CMG: 656.95 (-8.72), GM: 35.45 (+0.03), BA: 146.98 (+5.79), SNDK: 76.84 (+0.06), VRX.TO: 129.04 (-25.17)

Chipotle, Yahoo Sink On Price Target Cuts
at Investor's Business Daily - Wed Oct 21, 3:32PM CDT
Stocks sold off into the close after moving little in either direction through most of Wednesday's session. The Nasdaq lagged with an 0.8% loss, while the S&P 500 gave up 0.6% and the Dow Jones industrial average shed 0.3%. Volume was higher across...
AMZN: 565.45 (+9.68), VRX: 98.62 (-19.99), HA: 33.43 (+0.56), MANH: 71.01 (+0.93), UAL: 55.77 (+1.22), UA: 92.35 (-6.80), YHOO: 31.72 (+0.60), SWI: 58.22 (-0.09), CMG: 656.95 (-8.72), MCD: 110.62 (+8.08), GM: 35.45 (+0.03), GOOGL: 681.49 (+9.69), MSFT: 48.68 (+1.48), RACE: 55.91 (+0.91)

Another Biotech Sets Off More Selling
at The Street - Wed Oct 21, 3:10PM CDT
Market is feeling very jittery.
BLUE: 78.80 (-1.98), YHOO: 31.72 (+0.60), AMZN: 565.45 (+9.68), TSLA: 213.03 (+2.94), VRX: 98.62 (-19.99), SDS: 20.21 (-0.71), IBM: 144.36 (+3.44), FB: 98.66 (+1.55), CMG: 656.95 (-8.72), GM: 35.45 (+0.03), GOOGL: 681.49 (+9.69), BA: 146.98 (+5.79)

Biotech Stocks Slump Again on Valeant's 'Smoking Gun'
at The Street - Wed Oct 21, 3:02PM CDT
Biotech stocks were in the crossfire again on Wednesday as investors fled. But this time Hillary Clinton wasn't to blame.
KO: 43.57 (+1.38), VRX: 98.62 (-19.99), F: 15.60 (+0.19), KMB: 120.73 (+2.64), PFE: 33.16 (-0.30), IBB: 303.90 (-0.56), FCAU: 15.24 (+0.04), LLY: 76.75 (-0.26), TM: 125.32 (+1.62), BMY: 63.13 (+0.62), BA: 146.98 (+5.79), GM: 35.45 (+0.03), ABBV: 53.25 (-0.58), HMC: 33.02 (+0.32), RACE: 55.91 (+0.91)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LAZ Parking and indiGOtech's Bold EV Charging Move

EV Chargers: The Future Parked Closer? I've been around the block more times than a cabbie in Manhattan rush hour, and let me tell you, when it comes to EVs, folks are still playing catch-up. But here's a kicker—LAZ Parking and indiGOtech have decided they're not gonna wait around. This joint venture of theirs aims to sock some sense into the old condo complex parking...

Knexus Teams with Google Cloud to Boost Public Sector AI

Kicking Off a New Era for AI in Government There's a fresh wind blowing in how government agencies approach artificial intelligence, and it’s got Knexus and Google Cloud’s Gemini initiative written all over it. Set in Vienna, Virginia, the announcement rolls out a heavy-hitting collaboration that might just rewire how public sectors handle data. October 20, 2026,...

Hyliion Legal Woes Shake Investor Confidence

Legal Storm Brews Over Hyliion Investments If you think riding the stock market is like sailing a calm sea, wake up. Hyliion Holdings Corp. (NYSE:HYLN) finds itself steaming headlong into rough waters. A securities class action lawsuit, Olmeta v. Hyliion Holdings Corp., accuses the company of embellishing its ambitions. The lawsuit cites potential wrongdoing in a...

Millrose Investors Face Unveiling of Financial Missteps

A Cold Shower for Millrose Properties' Investors Investing in Millrose Properties, Inc. (NYSE: MRP) didn't quite pan out as some folks hoped. On the heels of Hunterbrook's report about dubious deals, the Company's stock tumbled 8.53%, smacking investors with a not-so-gentle reminder of market realities. Sure, stocks can dip and dive like a rollercoaster, but when it...

DARPA Pumps $10.7M into RxMP's Hemorrhage Control Drug

RxMP Therapeutics Lands a DARPA Deal Would you look at that—RxMP Therapeutics just got handed a load of cash thanks to some good old government backing. Up to $10.7 million from DARPA is no chump change. It's like finding a lifeboat right when you're treading water out there in the big bad sea. This award under the RAPIID program is set to move the needle for RxMP’s...

Software Tax Hits Enterprises: Costly Control Concerns

Unanticipated Software Costs: Who's in Charge? Picture this: you're running a tech setup at a major corporation, but the software changes thrust upon you aren't anything you would've chosen freely. Yeah, that's about one in four dollars from your hot little budget spent on tweaks and adjustments you didn’t ask for. And it's not as glamorous as it sounds—more like a...

PG&E Delivers $26M Climate Credit to Small Biz

California's Big Move for Small Businesses In a world where every dollar counts, small businesses across Northern and Central California are getting a helping hand. Pacific Gas and Electric Company (PG&E) is stepping up with a tidy little climate credit thanks to the state's Cap-and-Invest Program. Eligible businesses are automatically set to receive a $36.18 credit off...

Top Gun F/A-18 Super Hornet Lands at Palm Springs

Aviation Marvel Now Anchored at Palm Springs There's something electric about standing next to a piece of history, especially when it involves the thunderous scream of an F/A-18 Super Hornet. The Palm Springs Air Museum is pulling back the curtains on an experience that's got aviation buffs and Top Gun fans buzzing like bees. On November 7, 2026, this central hub of...

DICK'S Sporting Goods Faces Legal Challenges in Securities Suit

Trouble Brewing at DICK'S Sporting Goods Wall Street's not only about the wins. There are moments when the market throws a curveball, and right now, DICK'S Sporting Goods is facing a fast one. DJS Law Group just laid out a class action lawsuit accusing them of bending the securities law rules. It ain't pretty when a company gets tangled up in legal battles, but it's...

BRAC Bank Taps Finastra for Trade Finance Transformation

Bangladesh's BRAC Bank Embarks on Tech Transformation If ever there was a time for a bank to shake things up, BRAC Bank in Bangladesh decided it's now. Partnering up with Finastra, they're on a mission to modernize their trade finance operations, and they're banking on these changes to keep them relevant and competitive in a shaky global economy. Streamlining Trade...